Pharmaceutical company says this and similar lawsuits are “premised on junk science that conflicts with decades of independent, peer‑reviewed research.” ...

CDSCO approval is required before drugs, medical devices, and related products can be manufactured or sold in India. The ...

Just a few days after the Caldwell County Sheriff's Office warned of what they described as bold and professional-looking scams, multiple other sheriff's offices in the region issued scam alerts.

At a recent dinner meeting, an Emporia couple and a club member were recognized by the Emporia Sertoma Club for their outstanding service. The club also recognized several students from ...

Peptilogics' PLG0206 is a first-in-class anti-biofilm drug candidate being studied in patients with prosthetic joint infection (PJI), the first of multiple potential medical device-related infections ...

Operio Group has signed a distribution agreement with Schaefer Technologies, a manufacturer of semi-automatic encapsulation equipment. Operio Group, a holding company building a global group of brands ...

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced ...

HLP004 is an investigational intramuscular deuterated serotonergic agonist designed to activate serotonin pathways believed to promote neuroplasticity. The program is being developed as a potential ...

University of Ibadan law graduate Anita Babalola earned Second Class Upper and shared lessons on LinkedIn about resilience, growth, and her A-grade project.

NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...

Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...